ENDRA Life Sciences Inc.
NDRA
$3.98
$0.529915.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 412.01% | -52.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 184.74% | -32.36% | |||
| Operating Income | -184.74% | 32.36% | |||
| Income Before Tax | -76.25% | -5.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -76.25% | -5.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -76.25% | -5.60% | |||
| EBIT | -184.74% | 32.36% | |||
| EBITDA | -186.19% | 32.61% | |||
| EPS Basic | 19.39% | 93.33% | |||
| Normalized Basic EPS | 19.39% | 93.33% | |||
| EPS Diluted | 19.39% | 93.33% | |||
| Normalized Diluted EPS | 19.39% | 93.33% | |||
| Average Basic Shares Outstanding | 118.64% | 1,482.05% | |||
| Average Diluted Shares Outstanding | 118.64% | 1,482.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||